Clinical trials: Rivaroxaban
Stroke, Systemic Embolism
NOAC Portuguese Real World Study
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
- Conditions
- Stroke, Systemic Embolism, Major Bleeding
- Trial name
- NCT04808934
- Testing
- Apixaban, dabigatran, rivaroxaban
- Sponsor
- Pfizer
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
The purpose of the study is to assess the safety and efficacy of rivaroxaban-based versus warfarin-based antithrombotic regimens on outcomes of patients with left ventricle thrombosis following acute ST elevation myocardial…
- Trial name
- REWARF-STEMI (NCT05705089)
- Testing
- Rivaroxaban 15 MG, Warfarin
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Cancer-associated Thrombosis, Venous Thromboembolism
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM)…
- Conditions
- Cancer-associated Thrombosis, Venous Thromboembolism, Gynecologic Cancer, Ovarian Cancer
- Trial name
- GynCAT (NCT06284343)
- Testing
- Anticoagulant
- Where
- Italy
- Volunteers
- 1,800 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioma, Malignant
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment, especially in the months after surgery.
- Trial name
- NCT06196918
- Testing
- Rivaroxaban 10 MG
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Venous Thromboembolism
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
- Trial name
- COVET (NCT03196349)
- Testing
- Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pulmonary Embolism
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04879407
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 98,947 people
- Sponsor
- Brigham and Women's Hospital
Atherosclerosis, Coronary
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
The specific mechanistic benefit of rivaroxaban versus other FXa inhibitors on atherothrombotic events remain unclear. Therefore plan to initiate a prospective, randomized study to investigate the effect of rivaroxaban and…
- Trial name
- NCT06986369
- Testing
- Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
Atrial Fibrillation
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others.
- Trial name
- COBRRA-AF (NCT04642430)
- Testing
- Apixaban, Rivaroxaban
- Where
- 8 sites in Canada
- Volunteers
- 3,018 people
- Sponsor
- Ottawa Hospital Research Institute
Anticoagulation
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
- Trial name
- NCT02640222
- Testing
- VKA, Apixaban, dabigatran
- Where
- France
- Volunteers
- 321,501 people
- Sponsor
- Bristol-Myers Squibb
Post-Operative Atrial Fibrillation
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to…
- Trial name
- ATLAS (NCT02701062)
- Testing
- AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
- Where
- 22 sites in United States
- Volunteers
- 562 people
- Sponsor
- AtriCure, Inc.
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Limb Ischemia
Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening Ischemia
The goal of this clinical trial is to compare the effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone in patients aged 40-70 years with chronic limb-threatening ischemia, diabetes mellitus, hypertension, and…
- Trial name
- NCT07832578
- Testing
- Aspirin tablet, Low-Dose Rivaroxaban Plus Aspirin,
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- King Edward Medical University
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I
- Trial name
- RithMM (NCT03428373)
- Testing
- Rivaroxaban, ASA
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Intracardiac Thrombus
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (< 16 years old) diagnosed with intracardiac thrombosis.
- Trial name
- NCT06371170
- Testing
- Rivaroxaban
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero, Universitaria Ospedali Riuniti
Postpartum Period, Cesarean Section Surgery
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
Pregnancy and the postpartum period increase venous thromboembolism (VTE) risk. After cesarean section, low-molecular-weight heparin (LMWH; enoxaparin) is commonly used for short-term thromboprophylaxis, but it requires daily…
- Conditions
- Postpartum Period, Cesarean Section Surgery, VTE (Venous Thromboembolism)
- Trial name
- NCT07820670
- Testing
- Rivaroxaban, Enoxaparin 40 mg
- Where
- Israel
- Volunteers
- 62 people
- Sponsor
- Wolfson Medical Center
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine